Roche Holding AG

We maintain a bullish medium-term bias in Stage 2 corrective reset as price consolidates around the 9 and 20 EMAs and the rising 50 DMA, reflecting structural repair within the long-term uptrend. Near-term, the stock is range-bound with flat EMAs and neutral momentum, offering no clear execution edge. We will stalk pullbacks into the EMA and 50 DMA confluence for tactical entry. Key risks include a decisive breakdown below these moving averages, which would signal deeper correction and potential transition to Stage 3.

• ↑Pharma revenue reached CHF 35.6 B, up 9% YoY; international sales +13%.
• ↑10 pipeline molecules moved into Phase III, signaling robust R&D momentum.
• ↓Diagnostics revenues plunged 27% in China; single-digit decline expected in 2025.